↓ Skip to main content

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia

Overview of attention for article published in Frontiers in oncology, May 2023
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
Published in
Frontiers in oncology, May 2023
DOI 10.3389/fonc.2023.1161254
Pubmed ID
Authors

Natalia Timofeeva, Mary L. Ayres, Natalia Baran, Janice M. Santiago-O’Farrill, Gamze Bildik, Zhen Lu, Marina Konopleva, Varsha Gandhi

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 3 21%
Student > Ph. D. Student 2 14%
Librarian 1 7%
Professor > Associate Professor 1 7%
Unspecified 1 7%
Other 0 0%
Unknown 6 43%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 21%
Chemical Engineering 1 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Unspecified 1 7%
Agricultural and Biological Sciences 1 7%
Other 1 7%
Unknown 6 43%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 May 2023.
All research outputs
#21,321,749
of 26,173,059 outputs
Outputs from Frontiers in oncology
#11,700
of 22,919 outputs
Outputs of similar age
#307,442
of 409,502 outputs
Outputs of similar age from Frontiers in oncology
#472
of 1,156 outputs
Altmetric has tracked 26,173,059 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,919 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 409,502 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,156 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.